跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
AURO-DAPAGLIFLOZIN - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
AURO-DAPAGLIFLOZIN
Authorized
STANDARD
AURO-DAPAGLIFLOZIN
auro pharma inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
fc779e6e0944587d
Company
auro pharma inc
Type
Standard
Approval Details
Approval Id
fc779e6e0944587d
Drug Approval Canada Name
AURO-DAPAGLIFLOZIN
Product Name
AURO-DAPAGLIFLOZIN
Status
Marketed
Status Date
2023-05-16
Original Market Date
2023-05-16
Din
02531402
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
68:20.18
Atc Original
A10BK01 DAPAGLIFLOZIN
Atc Name
a 10 bk 01
Aig Number
0156370001
Company Name
auro pharma inc
Company Address
3700 Steeles Avenue West, Suite 402, Woodbridge, Ontario, Canada, L4L 8K8
Active Ingredients
DAPAGLIFLOZIN
5 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
fc779e6e0944587d
Type
Standard
Back to Health Canada Approvals